EFFECT OF ALL-TRANS RETINOIC ACID WITH CHEMOTHERAPY BASED ON PACLITAXEL AND CISPLATIN AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AND EXPRESSION OF RAR-ALFA AND RAR-BETA AS RESPONSE BIOMARKER: